Chemically defined and growth factor-free system for highly efficient endoderm induction of human pluripotent stem cells.

IF 5.9 2区 医学 Q1 CELL & TISSUE ENGINEERING Stem Cell Reports Pub Date : 2025-01-14 Epub Date: 2024-12-26 DOI:10.1016/j.stemcr.2024.11.012
Zhiju Zhao, Fanzhu Zeng, Yage Nie, Gang Lu, He Xu, He En, Shanshan Gu, Wai-Yee Chan, Nan Cao, Jia Wang
{"title":"Chemically defined and growth factor-free system for highly efficient endoderm induction of human pluripotent stem cells.","authors":"Zhiju Zhao, Fanzhu Zeng, Yage Nie, Gang Lu, He Xu, He En, Shanshan Gu, Wai-Yee Chan, Nan Cao, Jia Wang","doi":"10.1016/j.stemcr.2024.11.012","DOIUrl":null,"url":null,"abstract":"<p><p>Definitive endoderm (DE) derived from human pluripotent stem cells (hPSCs) holds great promise for cell-based therapies and drug discovery. However, current DE differentiation methods required undefined components and/or expensive recombinant proteins, limiting their scalable manufacture and clinical use. Homogeneous DE differentiation in defined and recombinant protein-free conditions remains a major challenge. Here, by systematic optimization and high-throughput screening, we report a chemically defined, small-molecule-based defined system that contains only four components (4C), enabling highly efficient and cost-effective DE specification of hPSCs in the absence of recombinant proteins. 4C-induced DE can differentiate into functional hepatocytes, lung epithelium, and pancreatic β cells in vitro and multiple DE derivatives in vivo. Genomic accessibility analysis reveals that 4C reconfigures chromatin architecture to allow key DE transcription factor binding while identifying TEAD3 as a novel key regulator of the process. This system may facilitate mass production of DE derivatives for drug discovery, disease modeling, and cell therapy.</p>","PeriodicalId":21885,"journal":{"name":"Stem Cell Reports","volume":" ","pages":"102382"},"PeriodicalIF":5.9000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cell Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.stemcr.2024.11.012","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

Definitive endoderm (DE) derived from human pluripotent stem cells (hPSCs) holds great promise for cell-based therapies and drug discovery. However, current DE differentiation methods required undefined components and/or expensive recombinant proteins, limiting their scalable manufacture and clinical use. Homogeneous DE differentiation in defined and recombinant protein-free conditions remains a major challenge. Here, by systematic optimization and high-throughput screening, we report a chemically defined, small-molecule-based defined system that contains only four components (4C), enabling highly efficient and cost-effective DE specification of hPSCs in the absence of recombinant proteins. 4C-induced DE can differentiate into functional hepatocytes, lung epithelium, and pancreatic β cells in vitro and multiple DE derivatives in vivo. Genomic accessibility analysis reveals that 4C reconfigures chromatin architecture to allow key DE transcription factor binding while identifying TEAD3 as a novel key regulator of the process. This system may facilitate mass production of DE derivatives for drug discovery, disease modeling, and cell therapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
化学定义的无生长因子系统,用于高效的人多能干细胞内胚层诱导。
来自人类多能干细胞(hPSCs)的最终内胚层(DE)在基于细胞的治疗和药物发现方面具有很大的前景。然而,目前的DE分化方法需要未定义的成分和/或昂贵的重组蛋白,限制了它们的可扩展制造和临床应用。在定义蛋白和重组蛋白无条件下均质DE分化仍然是一个主要挑战。在这里,通过系统优化和高通量筛选,我们报告了一个化学定义的、基于小分子的定义系统,它只包含四个组分(4C),在没有重组蛋白的情况下,能够高效和经济地对hPSCs进行DE规范。4c诱导的DE在体外可分化为功能性肝细胞、肺上皮细胞和胰腺β细胞,在体内可分化为多种DE衍生物。基因组可及性分析显示,4C重新配置染色质结构,允许关键DE转录因子结合,同时确定TEAD3是该过程的一个新的关键调节因子。该系统可促进用于药物发现、疾病建模和细胞治疗的DE衍生物的大规模生产。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Stem Cell Reports
Stem Cell Reports CELL & TISSUE ENGINEERING-CELL BIOLOGY
CiteScore
10.50
自引率
1.70%
发文量
200
审稿时长
28 weeks
期刊介绍: Stem Cell Reports publishes high-quality, peer-reviewed research presenting conceptual or practical advances across the breadth of stem cell research and its applications to medicine. Our particular focus on shorter, single-point articles, timely publication, strong editorial decision-making and scientific input by leaders in the field and a "scoop protection" mechanism are reasons to submit your best papers.
期刊最新文献
A versatile in vivo platform for reversible control of transgene expression in adult tissues. Optimized prime editing of the Alzheimer's disease-associated APOE4 mutation. Glycogen synthase kinase-3 inhibition and insulin enhance proliferation and inhibit maturation of human iPSC-derived cardiomyocytes via TCF and FOXO signaling. Elevated hematopoietic stem cell frequency in mouse alveolar bone marrow. Nascent matrix deposition supports alveolar organoid formation from aggregates in synthetic hydrogels.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1